Kapil Dhingra
Chairman at LAVA THERAPEUTICS N.V.
Net worth: 619 766 $ as of 31/03/2024
Profile
Kapil Dhingra founded Kapital Consulting LLC in 2008, where he is working as Managing Member from 2011.
Dr. Dhingra also founded Kirilys Therapeutics, Inc., where he is working as Director.
Dr. Dhingra also currently works at LAVA Therapeutics NV, as Non-Executive Chairman from 2021, MEDIAN Technologies SA, as Director from 2017, Sarcoma Alliance for Research through Collaboration, as Director, and various other companies.
Dr. Dhingra also formerly worked at Exosome Diagnostics, Inc., as Chairman from 2012 to 2018, YM BioSciences, Inc., as Independent Director from 2012 to 2013, Five Prime Therapeutics, Inc., as Independent Director from 2015 to 2021, and various other companies.
Dr. Dhingra received his undergraduate degree and doctorate degree from All India Institute of Medical Sciences.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
AUTOLUS THERAPEUTICS PLC
0.04% | 01/03/2023 | 73,537 ( 0.04% ) | 469 166 $ | 31/03/2024 |
LAVA THERAPEUTICS NV
0.11% | 28/02/2023 | 30,000 ( 0.11% ) | 99 900 $ | 31/03/2024 |
16/05/2023 | 10,000 ( 0.02% ) | 50 700 $ | 31/03/2024 | |
REPLIMUNE GROUP, INC.
-.--% | 01/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
CARGO THERAPEUTICS, INC.
-.--% | 15/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Kapil Dhingra active positions
Companies | Position | Start |
---|---|---|
MEDIAN TECHNOLOGIES | Director/Board Member | 01/06/2017 |
REPLIMUNE GROUP, INC. | Director/Board Member | 01/07/2017 |
BLACK DIAMOND THERAPEUTICS, INC. | Director/Board Member | 19/01/2021 |
LAVA THERAPEUTICS N.V. | Chairman | 22/02/2021 |
CARGO THERAPEUTICS, INC. | Director/Board Member | 15/04/2024 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Director/Board Member | 01/08/2014 |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The private company is based in Abingdon, UK and was founded in 2015. | Director/Board Member | 01/07/2017 |
Median Technologies, Inc.
Median Technologies, Inc. Medical/Nursing ServicesHealth Services Part of MEDIAN Technologies SA, Median Technologies, Inc. provides medical imaging services. The private company is based in Burlington, MA. The CEO of the company is Fredrik Bjjorn Brag. | Director/Board Member | 01/06/2017 |
Mariana Oncology, Inc.
Mariana Oncology, Inc. Pharmaceuticals: MajorHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Director/Board Member | 03/02/2022 |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Former positions of Kapil Dhingra
Companies | Position | End |
---|---|---|
░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Kapil Dhingra
All India Institute of Medical Sciences | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 7 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
MEDIAN TECHNOLOGIES | Health Services |
REPLIMUNE GROUP, INC. | Health Technology |
BLACK DIAMOND THERAPEUTICS, INC. | Health Technology |
AUTOLUS THERAPEUTICS PLC | Health Technology |
LAVA THERAPEUTICS N.V. | Health Technology |
CARGO THERAPEUTICS, INC. | Health Technology |
Private companies | 29 |
---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Health Technology |
SARcode Bioscience, Inc.
SARcode Bioscience, Inc. Pharmaceuticals: MajorHealth Technology SARcode Bioscience, Inc., develops biopharmaceutical products. Its program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases. The company was founded by Thomas Gadek and John P. Burnier in 2006 and is headquartered in Brisbane, CA. | Health Technology |
BlinkBio, Inc.
BlinkBio, Inc. Pharmaceuticals: MajorHealth Technology BlinkBio, Inc. operates as a biotechnology company. It develops medicines for the treatment of cancer and other diseases. The company was founded by Maneesh Pingle, Francis Barany, Don Bergstrom and Michael Gargano in 2009 and is headquartered in Juno Beach, FL. | Health Technology |
Les Laboratoires Servier SAS
Les Laboratoires Servier SAS Pharmaceuticals: MajorHealth Technology Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Health Technology |
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX. | Consumer Services |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Avon Foundation For Women
Avon Foundation For Women Investment Trusts/Mutual FundsMiscellaneous Avon Foundation For Women provides granting services. The non-profit company is based in New York, NY. | Miscellaneous |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | Health Technology |
EpiTherapeutics ApS
EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Health Services |
Advanced Accelerator Applications SA
Advanced Accelerator Applications SA Medical SpecialtiesHealth Technology Advanced Accelerator Applications SA is a radiopharmaceutical company, which develops, produces and commercializes molecular nuclear medicine products. The firm offers research and development in medicinal and pharmaceutical therapeutic products mainly focusing in cardiology and neurology. It manufactures both diagnostic and therapeutic MNM products for commercialization. The company was founded by Stefano Buono in 2002 and is headquartered in Rueil-Malmaison Cedex, France. | Health Technology |
Kapital Consulting LLC | |
European Organisation for Research & Treatment of Cancer | |
The Cancer Prevention & Research Institute of Texas
The Cancer Prevention & Research Institute of Texas BiotechnologyHealth Technology Cancer Prevention & Research Institute of Texas provides cancer research and prevention programs and services. It is the state agency mandated to create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer. The company was founded in 2007 and is headquartered in Austin, TX. | Health Technology |
Institut Gustave Roussy EURL
Institut Gustave Roussy EURL Miscellaneous Commercial ServicesCommercial Services Institut Gustave Roussy EURL is a cancer research and treatment center that places innovation at the heart of its services. The private company is based in Chevilly-Larue, France, and has subsidiaries in France. The center has strong partnerships at national and international levels to provide high-value care to all its patients. Patients' rights are protected and guaranteed to ensure their autonomy, respect for their individual liberties, and dignity within the hospital. | Commercial Services |
Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded on May 28, 1997 and is headquartered in Pleasanton, CA. | Health Technology |
Sarcoma Alliance for Research through Collaboration | |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Health Technology |
Median Technologies, Inc.
Median Technologies, Inc. Medical/Nursing ServicesHealth Services Part of MEDIAN Technologies SA, Median Technologies, Inc. provides medical imaging services. The private company is based in Burlington, MA. The CEO of the company is Fredrik Bjjorn Brag. | Health Services |
Replimune Ltd.
Replimune Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Replimune Group, Inc., Replimune Ltd. is a British company that researches and develops cancer therapeutics. The private company is based in Abingdon, UK and was founded in 2015. | Commercial Services |
Mariana Oncology, Inc.
Mariana Oncology, Inc. Pharmaceuticals: MajorHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Health Technology |
Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. Medical/Nursing ServicesHealth Services Kirilys Therapeutics, Inc. is an American preclinical-stage biopharmaceutical company that focuses on developing multiple precision oncology assets. The company is based in California and is committed to advancing the field of oncology. The company's initial asset is KRLS-017, a novel CDK7 inhibitor that has the potential to improve the treatment of multiple cancers. Kirilys Therapeutics was founded by Takeshi Takahashi, Brian Taylor Slingsby, and Kapil Dhingra, with Brian Taylor Slingsby serving as the CEO since incorporation. | Health Services |
Algeta ASA
Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
NCI Experimental Therapeutics Program |
- Stock Market
- Insiders
- Kapil Dhingra